0.00Open0.05Pre Close0 Volume233 Open Interest25.00Strike Price0.00Turnover7395.00%IV349.73%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier-4DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0414Delta0.0232Gamma111.40Leverage Ratio-4.0383Theta0.0000Rho4.61Eff Leverage0.0000Vega
Biomea Fusion Stock Discussion
The pause on clinical trials seems to be a result of the explosion of industry regulations in recent years. From 2022 through 2024, the FDA has implemented "additional steps" to clinical trials, including bringing in outside agencies to help with oversight.
Red tape and bureaucracy, not BEMA, caused this pause. All the research I've done shows the pause was premature and overly cautious.
No comment yet